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Abstrat
Background/aim: This study was performed to identify the characteristics distinguishing fatal and nonfatal cases of patients diagnosed
with Crimean–Congo hemorrhagic fever (CCHF).
Materials and methods: A total of 92 patients with confirmed diagnosis of CCHF in 2009–2013 were included in the study.
Results: A high level of urea and aPTT on the third day of hospital stay, diarrhea, somnolence, and the interval from the beginning of the
symptoms to hospital admission were independently associated with fatality. Each 10-unit increase in aPTT and urea levels increased
the fatality rate by 3.379-fold and 1.236-fold, respectively. Delay in hospital admission increased the fatality rate 1.453-fold for each day
of delay. When comparing first and third admission-day laboratory values, the increase in leukocyte counts and the decrease in CPK,
urea, creatinine, aPTT, PT, INR, and hemoglobin levels were significant in nonfatal cases.
Conclusion: This study showed that the course of these laboratory tests helps us to predict the outcome of the disease. In a few days of
hospitalization, persistence or progress of the abnormal laboratory parameters may warn us about poor prognosis.
Key words: Crimean–Congo hemorrhagic fever, mortality, severity criteria

1. Introduction
Crimean–Congo hemorrhagic fever (CCHF) is a tickborne disease caused by a Nairovirus of the Bunyaviridae
family (1). The disease is endemic or potentially endemic
in 52 countries (2). Since 2002, CCHF has been a serious
problem in the central, northern, and eastern regions of
Turkey. Although the number of cases has increased year
by year, the case fatality rate has been reported as 5% on
average (3).
The clinical spectrum of CCHF varies from
asymptomatic or mild infections to severe disease and
death (4). In severe cases, hemorrhagic manifestations
develop 3–6 days after the onset of the illness. The mortality
rate is very broad, depending on the geographic region. It
has been reported to be between 5% and 30% in different
studies (3,5). The outcome of the disease is correlated with
high viral load (>108 copies/mL), abnormal laboratory
values (thrombocytopenia, leucocytosis, elevated liver
enzymes, high CPK levels, prolonged aPTT, high INR,
etc.), and severe clinical signs or symptoms (hematemesis,
melena, hematuria, petechiae, somnolence, etc.) (6).
* Correspondence: sumeyye_yildiz@hotmail.com
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This study was performed to identify the different
characteristics of fatal and nonfatal cases and the factors
increasing the fatality rate of CCHF. The laboratory
parameters were also evaluated day by day after hospital
admission, and the effect of the changes in these parameters
for predicting the outcome was investigated.
2. Materials and methods
This retrospective study was carried out at the Ankara
Numune Education and Training Hospital, which is a
referral and tertiary care hospital in Turkey. A total of
92 patients with confirmed diagnosis of CCHF during
2009–2013 were included in the study. These patients
had compatible clinical presentation with CCHF and
positive viral RNA by RT-PCR or specific IgM antibodies
by ELISA in serum samples. Data of the patients was
collected from specifically designed follow-up charts and
patient files. Demographic, epidemiological, and clinical
characteristics, laboratory parameters, and treatment
and outcome of the patients were analyzed statistically.
A comparison was made between the characteristics of
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deceased and surviving patients, and the risk factors for
mortality were determined. In addition, the first and the
third admission-day laboratory parameters were evaluated
and the effect of the difference on the outcome was
established.
2.1. Statistical analysis
Patients were classified into 2 groups according to their
survival status: deceased, or discharged with recovery. SPSS
11.5 was used for statistical analysis. The Kolmogorov–
Smirnov test was used for numeric variables if they
were close to normal. The numeric data was expressed
as median (min–max) and medium, and the categorical
data as number and percentages. Student’s test and the
Mann–Whitney U test were used for median and medium
variables with groups. Pearson’s chi-square test or Fisher’s
exact test was used for categorical variables. First and third
day laboratory values were compared using the dependent
t-test and Wilcoxon test. Receiver operating characteristic
(ROC) curve analysis was performed for values that were
statistically significant. Sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) were calculated. Cox regression was used to model
outcomes. The time start-point was the patient’s admission
to the hospital and the time end-point was either death or
discharge from hospital. For multivariate analysis, P < 0.25
in univariate analyses was tested to determine independent
risk factors.
3. Results
The mean age of the patients was 50 years, and 46 (50%)
were male. Eighty-one patients (88.0%) were involved in
handling livestock or farming. A history of tick bites was
present for 64 patients (69.6%). Of the 92 patients, 15 died
and 77 survived. The case fatality rate was 16.3%. Fatal
cases were hospitalized for a mean of 4 days (range: 1–8)
before death.
Age, sex, tick contact, time from tick bite to appearance
of complaints, and comorbidities were similar between
fatal and nonfatal groups (P > 0.05). Duration of hospital
stay was shorter and the interval from the beginning of
symptoms to hospital admission was longer in fatal cases
(P = 0.01 and P = 0.007, respectively). Diarrhea, shortness
of breath, skin eruptions, bleeding, fever, and somnolence
were significantly more common in patients who died
(Table 1). Biochemical and hematological laboratory
values of the 2 groups were also compared to determine
fatality predictors. In fatal cases, platelet count and
fibrinogen were significantly lower, whereas ALT, AST,
LDH, urea, aPTT, PT, and INR were significantly higher
than in nonfatal cases on both the first and the third
admission days (Table 2).
Among 48 patients who underwent abdominal
ultrasonography (US), 18 (38%) had abnormal findings.

The most common US findings were pericholecystic
fluid and an increase in the thickness of the gallbladder
wall (13/18 patients). Nine patients had hepatomegaly.
Splenomegaly was detected in 4 patients. Among 86
patients with PA chest X-rays, 17 (20%) had radiological
abnormalities. These X-ray and US findings were observed
to be higher in the fatal group than in the nonfatal
group (Table 3). In 9 patients with somnolence, cranial
computed tomography (CT) was performed, although no
pathological findings were detected.
All patients in this study received only supportive
therapy. Nearly half of the patients (n = 45, 49%) received
blood or blood product infusions. Antibiotic treatment
was started for one-third of the patients with the suspicion
of secondary bacterial infections. Almost all fatal cases
(14/15) had one or more complications. The rates of
antibiotic therapy, blood transfusion, and complications
were significantly higher in fatal cases (Table 3).
In comparing the first and third admission-day
laboratory values, an increase of WBC counts and the
decrease of CPK, urea, creatinine, aPTT, PT, INR, and Hb
levels were significant in nonfatal cases. However, there
was no significant difference between the first and third
admission-day laboratory values in the fatal group (Table
4).
ROC curve analysis was performed for all the
statistically significant parameters. Obtained cut-off values
are presented in Table 5. The Cox model was used for
fatality analysis. The time start-point was admission to the
hospital and the end-point was either death or discharge
from hospital. Urea and aPTT on the third admission day,
diarrhea, somnolence, and the interval from the beginning
of the symptoms to hospital admission were independently
associated with fatality. Each 10-unit increase in aPTT
and urea levels increased the fatality rate 3.379-fold and
1.236-fold, respectively. In addition, delay of admission to
hospital increased the fatality rate 1.453-fold for each day
(Table 6).
4. Discussion
CCHF is an endemic disease in rural areas of Turkey. One
major risk group is farmers, and the most common method
of transmission is exposure to ticks (3,7). A history of tick
bite was reported as 68.7% in Turkish patients, similarly to
this study (3). Initial symptoms of CCHF are nonspecific,
characterized by fever, weakness, headache, myalgia,
nausea, and vomiting. In severe cases, hemorrhages
develop 3–6 days after the onset of the disease (4,8). In
this study, one of the prominent symptoms was skin
lesion, which was more common in comparison with our
previous study (8). Skin lesions were detected in 41% of our
patients and petechiae were the most frequent type. Akyol
et al. evaluated 35 patients and found that 83.3% of the
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Table 1. Demographic, epidemiological, and clinical characteristics of CCHF patients.
Characteristics

Total cases (%)
n = 92

Nonfatal cases (%)
n = 77

Fatal cases (%)
n = 15

P-value

Male

46 (50)

37/77 (48.1)

9/15 (60.0)

0.397

Age, years (mean)

49.4 ± 17.4

48.3 ± 18.0

55.1 ± 13.2

0.166

Living in rural areas

85 (92.4)

71 (92.2)

14 (93.3)

1.000

Handling livestock/farming

81 (88.0)

67 (87.0)

14 (93.3)

0.685

Tick exposure

64 (69.6)

55 (71.4)

9 (60.0)

0.376

Time from tick bite to onset of complaints
(days)

3.8 ± 2.8

3.9 ± 2.8

3.3 ± 3.04

0.489

Interval from the beginning of
symptoms to hospital admission (days)

2.7 ± 2.1

2.5 ± 2.1

3.9 ± 2.2

0.007

Comorbidities

21 (22.8)

15 (19.5)

6 (40.0)

0.099

Hospital stay (days)

6.7 ± 3.7

7 ± 3. 4

4 ± 2.8

0.010

Fever

80 (87)

66 (85.7)

14 (93.3)

0.683

Fatigue

85 (92.4)

71 (92.2)

14 (93.3)

1.000

Nausea/vomiting

58 (63)

46 (59.7)

12 (80.0)

0.137

Diarrhea

26 (28.3)

15 (19.5)

11 (73.3)

<0.001

Headache

53 (57.6)

41 (53.2)

12 (80.0)

0.055

Shortness of breath

23 (25.0)

16 (20.8)

7 (46.7)

0.050

Skin eruption

38 (41.0)

28 (36.4)

10 (66.7)

0.029

Bleeding (any kind)

28 (30.4)

18 (23.4)

10 (66.7)

0.002

Fever, temperature >38 °C

44 (47.8)

33 (42.9)

11 (73.3)

0.031

Somnolence

9 (9.8)

3 (3.9)

6 (40.0)

<0.001

Respiratory abnormalities

21 (23.0)

13 (16.9)

8 (53.3)

0.005

Hepatosplenomegaly

7 (8.0)

6 (7.8)

1 (6.7)

1.000

Petechiae

32 (35.0)

23 (29.9)

9 (60.0)

0.025

Ecchymosis

16 (17.0)

10 (13.0)

6 (40.0)

0.021

Maculopapular rash

7 (8.0)

6 (7.8)

1 (6.7)

1.000

Epistaxis

10 (10.9)

8 (10.4)

2 (13.3)

0.664

Gingival bleeding

12 (13.0)

8 (10.4)

4 (26.7)

0.103

Melena

10 (10.9)

3 (3.9)

7 (46.7)

<0.001

Vaginal bleeding

4 (4.3)

3 (3.9)

1 (6.7)

0.516

Hematemesis

3 (3.3)

1 (1.3)

2 (13.3)

0.068

Subcutaneous hematoma

4 (4.3)

2 (2.6)

2 (13.3)

0.123

Hematuria

10 (10.9)

5 (6.5)

5 (33.3)

0.009

Symptoms

Clinical findings

Skin lesions

Bleeding

330

KAZANCIOĞLU et al. / Turk J Med Sci
Table 2. Comparison of laboratory findings in fatal and nonfatal cases.
First day

Third day

Nonfatal cases
(n = 77)

Fatal cases
(n = 15)

P-value

Nonfatal cases
(n = 77)

Fatal cases
(n = 15)

P-value

WBC (/µL)

2899 ± 2183

4935 ± 4152

0.052

3196 ± 1737

4100 ± 3459

0.917

Hb (g/dL)

13.4 ± 1.92

13.3 ± 2.97

0.940

12.9 ± 1.79

11.7 ± 2.42

0.034

PLT (/µL)

79,610 ± 59,725

27,571 ± 13,754

<0.001

73,610 ± 46,811

31,714 ± 31,145

<0.001

ALT (U/L)

92 ± 84

210 ± 218

0.016

110 ± 114

331 ± 339

<0.001

AST (U/L)

195 ± 187

699 ± 764

<0.001

245 ± 436

1081 ± 1006

<0.001

CPK (U/L)

564 ± 836

1111 ± 1246

0.129

379 ± 692

2205 ± 3349

<0.001

LDH (U/L)

541 ± 381

1561 ± 1227

<0.001

657 ± 1018

1572 ± 703

<0.001

Creatinine (mg/dL)

0.99 ± 0.91

1.4 ± 1.05

0.025

0.90 ± 0.89

1.7 ± 1.43

<0.001

Urea (mg/dL)

31.7 ± 24.8

62.3 ± 50.78

0.002

24.7 ± 14.8

71.5 ± 57.94

<0.001

aPTT (s)

36.3 ± 9.09

55.0 ± 13.38

<0.001

32.6 ± 6.9

53.7 ± 14.16

<0.001

PT (s)

12.8 ± 1.69

15.2 ± 2.64

<0.001

11.9 ± 1.59

14.9 ± 4.38

<0.001

INR

1.0 ± 0.15

1.3 ± 0.22

<0.001

1.0 ± 0.10

1.3 ± 0.38

<0.001

Fibrinogen (mg/dL)

281 ± 84

207 ± 71

<0.001

218 ± 94

0.013

290 ± 85

P < 0.025 was considered statistically significant.
WBC: White blood cells; Hb: hemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CPK: creatine
phosphokinase; LDH: lactate dehydrogenase; aPTT: activated partial thromboplastin time; PT: prothrombin time; INR: international
normalized ratio.
CRP and D-Dimer were tested only on the first day. They were not found to be associated with fatality. P-values were 0.963 and 0.294,
respectively.

Table 3. Radiological characteristics, complications, and treatment of CCHF patients
Characteristics

All cases (%)

Nonfatal cases (%)

Fatal cases (%)

P-value

US abnormality

18/48 (38.0)

12/41 (29.3)

6/7 (85.7)

0.008

Chest X-ray abnormality

17/86 (20.0)

10/73 (13.7)

7/13 (53.8)

0.003

Antibiotic treatment

28/92 (30.0)

16 (20.8)

12 (80.0)

<0.001

Transfusion

45/92 (49.0)

30 (39.0)

12 (80.0)

<0.001

Complications (any kind)

34/92 (36.9)

20 (26.0)

14 (93.3)

<0.001

Bleeding

20/92 (21.7)

9 (11.7)

11 (73.3)

<0.001

Secondary infections

20/92 (21.7)

11 (14.3)

9 (60.0)

<0.001

Renal failure

14/92 (15.2)

4 (5.2)

10 (66.7)

<0.001

Mechanical ventilation

8/92 (8.7)

0 (0.0)

8 (53.3)

<0.001
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Table 4. Comparison of the first and third admission-day laboratory values in nonfatal and fatal groups.
Nonfatal cases (n = 77)

Fatal cases (n = 15)

First day

Third day

P-value

First day

Third day

P-value*

WBC (/µL)

2899 ± 2183

3196 ± 1737

0.022

4935 ± 4152

4100 ± 3459

0.084

Hb (mg/dL)

13.4 ± 1.92

12.9 ± 1.79

0.002

13.3 ± 2.97

11.7 ± 2.42

0.050

PLT (/µL)

79,610 ± 59,725

73,610 ± 46,811

0.724

27,571 ± 13,754

31,714 ± 31,145

0.572

ALT (U/L)

92 ± 84

110 ± 114

0.370

210 ± 218

331 ± 339

0.064

AST (U/L)

195 ± 187

245 ± 436

0.566

699 ± 764

1081 ± 1006

0.198

CPK (U/L)

564 ± 836

379 ± 692

<0.001

1111 ± 1246

2205 ± 3349

0.028

LDH (U/L)

541 ± 381

657 ± 1018

0.843

1561 ± 1227

1572 ± 703

0.551

Creatinine (mg/dL)

0.99 ± 0.91

0.90 ± 0.89

<0.001

1.4 ± 1.05

1.7 ± 1.43

0.258

Urea (mg/dL)

31.7 ± 24.8

24.7 ± 14.8

<0.001

62.3 ± 50.78

71.5 ± 57.94

0.233

aPTT (s)

36.3 ± 9.09

32.6 ± 6.9

<0.001

55.0 ± 13.38

53.7 ± 14.16

0.730

PT (s)

12.8 ± 1.69

11.9 ± 1.59

<0.001

15.2 ± 2.64

14.9 ± 4.38

0.727

INR

1.0 ± 0.15

1.0 ± 0.10

<0.001

1.3 ± 0.22

1.3 ± 0.38

0.875

Fibrinogen (mg/dL)

281 ± 84

290 ± 85

0.094

207 ± 71

218 ± 94

0.451

*P < 0.025 was considered statistically significant.
Table 5. Cut-off levels for prognostic factors.
First day

Third day

Level

Sensitivity
Specificity

PPV
NPV

AUROC

Level

Sensitivity
Specificity

PPV
NPV

AUROC

PLT (/µL)

<30,000

85.7
81.8

46.2
96.9

0.840

<29,500

78.6
80.5

42.3
95.4

0.801

ALT (U/L)

>103

71.4
72.7

32.3
93.3

0.704

>105

85.7
64.9

30.8
96.2

0.815

AST (U/L)

>222

78.6
70.1

32.4
94.7

0.790

>331

85.7
83.1

48.0
97.0

0.896

CPK (U/L)

-

-

-

-

>566

78.6
83.1

45.8
95.5

0.859

>961

64.3
85.7

45.0
93.0

0.800

>709

100
75.3

42.4
100

Creatinine (mg/dL)

-

-

-

-

57.1
93.5

61.5
92.3

0.769

Urea (mg/dL)

>27.5

92.9
58.4

28.9
97.8

0.760

>26.5

100
64.9

34.1
100

0.901

aPTT (s)

>53.1

71.4
94.8

71.4
94.8

0.884

>37.6

92.9
84.4

52.0
98.5

0.932

PT (s)

>13.2

78.6
71.4

33.3
94.8

0.793

71.4
88.3

52.6
94.4

0.843

INR

>1.06

85.7
55.8

26.1
95.6

0.768

>1.05

78.6
79.2

40.7
95.3

0.817

Fibrinogen (mg/dL)

<226

71.4
80.5

40.0
93.9

0.773

<227

64.3
81.8

39.1
92.6

0.710

LDH (U/L)
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Table 6. The evaluation of all possible risk factors on survival (multivariate logistic regression analysis).
Odds ratio

95% CI

P-value

aPTT (s) (third day)*

3.379

1.758–6.494

<0.001

Urea (mg/dL) (third day)*

1.236

1.066–1.433

0.005

Diarrhea

6.875

1.600–29.538

0.010

Somnolence

6.310

1.531–25.999

0.011

Interval from the beginning of symptoms
to hospital admission, days**

1.453

1.058–1.995

0.021

*Effect on fatality for each 10-unit increase.
**Effect on fatality for each day of admission delay.

patients had one or multiple skin lesions (9). They reported
ecchymosis as 65.7%, petechiae or purpura as 57.1%, and
morbilliform rash as 31.4%. They also emphasized that
these lesions were seen at higher rates in extremities open
to trauma. The other striking symptom of our patients
was respiratory system findings. The rate for shortness
of breath was 25%, auscultation abnormalities were 23%,
and chest radiographic abnormalities were 19.8% in 86
patients. Radiographic pulmonary abnormalities were
more common in fatal cases. There are a few studies
about respiratory system involvement in CCHF patients.
In one of these studies, it was emphasized that cough
and dyspnea were more common symptoms and ARDS
could occur in patients with hemoptysis (10). Dogan et
al. reported pathological auscultation findings as 33.4%
(crackles: 31.5%, rhonchi: 1.9%) and chest radiographic
abnormalities as 33.3% (infiltrations: 17.6%) in CCHF
patients (11). They also found that respiratory complaints
were more common in patients who died. In this study,
gastrointestinal ultrasonic findings were also noteworthy.
Nearly one-third of the patients had an increase in the
thickness of the gallbladder wall and pericholecystic
fluid in their abdominal US imaging. Additionally, these
findings were more frequent in the fatal group. There is no
publication about radiological imaging of the abdomen in
CCHF. Thus, the precise involvement of the gastrointestinal
system with CCHF is not known.
CCHF is a fatal hemorrhagic syndrome. Reported
fatality rates range between 5% and 30% in different
studies (5,6). In this study, the fatality rate was found to
be 16.3%, which is higher than the average rate (5%) in
Turkey (12). Our hospital is one of the referral hospitals
for CCHF patients and mostly had severe cases transferred
to receive more intensive supportive treatment. Thus, our
fatality rate is above the average rate of Turkey. In this
study, diarrhea, shortness of breath, petechiae, ecchymosis,
and bleeding were found to be significantly more common
in the fatal group. Bleeding is an important factor for

prognosis. Nearly 30% of patients had complaints of
hemorrhage upon admission to hospital. Skin bleeding was
more common, including petechiae (34.8%), ecchymosis
(17.4%), and subcutaneous hematoma (4.3%). Melena,
hematuria, petechiae, and ecchymosis were significantly
more frequent in fatal cases. In several studies, the outcome
of the disease was shown to be correlated significantly with
somnolence and gastrointestinal bleeding (8,13,14).
There were statistically significant differences between
the 2 groups in clinical and laboratory variables. ALT, AST,
LDH, urea, aPTT, PT, and INR were significantly higher
in the fatal group, whereas platelet count and fibrinogen
were significantly lower. Although WBC count was higher
in the fatal group, there was no significant difference
compared to the nonfatal group. However, Swanepoel et
al. and Hatipoglu et al. found that high WBC count was a
predictor of fatality (13,14).
Cut-off levels of prognostic factors can help us to
predict the outcome of the disease. Platelet count and
aPTT are the mostly used predictive factors. In this study,
platelet counts lower than <30 × 109/L and aPTT higher
than 53.1 s were predictors of survival with high specificity
(81.8% and 94.8%) and high negative predictive value
(96.9% and 94.8%). There are different cut-off levels in the
literature. Ozturk et al. reported that aPTT of >65.7 s and
platelet counts of >17 × 109/L were predictors of survival
(15). Yılmaz et al. and Çevik et al. reported cut-off levels
of platelet counts of <90 × 109/L and <20 × 109/L and
aPTT levels of >34 s and >60 s for risk factors of mortality,
respectively (16). In our study, it was shown that the third
admission-day’s aPTT cut-off level (37.6 s) was more
important for prognosis of the disease (specificity 92.9%,
sensitivity 84.4%, NPV 98.5%).
When all possible risk factors for survival were
evaluated by multivariate logistic regression analysis,
the 5 most important survival parameters were, in
order, the third day’s aPTT and urea levels, somnolence,
complaints of diarrhea, and duration of complaints prior
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to hospitalization. A 10-unit increase of aPTT and urea
was associated with a 3.379-fold and 1.236-fold increase in
fatality rate, respectively. Each day of admission delay was
found to elevate fatality rate 1.453-fold. This means that
earlier admission to the hospital significantly improves
the patients’ outcome. Thus, it is important to provide
awareness and education to people living in endemic
areas. In other similar studies, somnolence, diarrhea,
melena, hematemesis, hematuria, elevated ALT and LDH,
prolonged aPTT, and decreased platelet count were found
as independent predictors associated with fatality by
multivariate analysis (8,14). High viral load was reported
as one of the most significant factors affecting the mortality
rate in CCHF (17). However, viral loads of the patients
could not be evaluated in this study, which is a weakness
of our study. The reason is that this is a retrospective study;
therefore, quantitative PCR could not be performed for
most of the patients.
In previous studies, deaths were reported to occur
between days 5 and 14 of the disease. In our patients, deaths

generally occurred on day 4 of hospitalization. Thus, we
analyzed the first and the third admission-day laboratory
parameters to find out the clinical significance of the
laboratory difference between the two days in fatal and
nonfatal cases. When the first and the third admission-day
laboratory values were compared, increase of WBC counts
and decrease of CPK, urea, creatinine, aPTT, PT, and INR
levels were significant in the nonfatal group. However, there
was no difference in the fatal group. This result suggests
that an improvement in abnormal laboratory values in the
3 days after hospital admission may be a valuable predictor
for survival. If there is no significant improvement, this
may show us that the outcome is probably poor.
In conclusion, there are many laboratory tests to
predict the fatality of patients with CCHF. Additionally,
this study showed that the course of these laboratory tests
also helps us to predict the outcome of the disease. In a
few days of hospitalization, persistence or progress of the
abnormal laboratory parameters may warn us about poor
prognosis.
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